白藜芦醇在慢性阻塞性肺疾病合并肺源性心脏病SD大鼠肺功能及心脏功能改善中的作用

doi:10.3969/j.issn.1007-3205.2020.08.004

摘要/Abstract

摘要： 目的白藜芦醇在慢性阻塞性肺疾病合并肺源性心脏病SD大鼠肺功能及心脏功能改善中的作用。
方法用成年雄性SD大鼠45只建立慢性阻塞性肺疾病合并肺源性心脏病模型，建模成功后随机分为白藜芦醇组、糖皮质激素组和对照组各15只。白藜芦醇组给予白藜芦醇灌胃治疗28 d，糖皮质激素组给予布地奈德雾化吸入28 d，对照组给予生理盐水灌胃28 d。比较3组治疗前后肺功能［肺顺应性（compliance of lung， CL）、最大呼气流量（peak expiratory flow, PEF）、最大呼气中段流量（maximal mid-expiratory flow curve， MMF）、0.3 s用力呼气容积/用力肺活量比值（forced expiratory volume in first 0.3 second/forced vital capacity,FEV0.3/FVC）］和心脏功能结构［左心室射血分数（left ventricular ejection fraction,LVEF）、左心室舒张末期内径（left ventricular end diastolic diameter, LVEDD）、室间隔厚度（interventricular septal thickness,IVST）和左心室后壁厚度（left ventricular posterior wall thickness,LVPWT）,右心室游离壁质量、左心室和室间隔质量，右心室/(左心室+室间隔)（right ventricle/（left ventricular+interventricular septum，RV/LV+S）］，观察不良反应发生情况。
结果干预后，3组CL、PEF 、MMF水平均低于干预前，FEV0.3/FVC水平高于干预前；白藜芦醇组CL、PEF 、MMF、FEV0.3/FVC水平高于糖皮质激素组和对照组，糖皮质激素组CL、PEF 、MMF、FEV0.3/FVC水平高于对照组（P＜0.05）。3组LVEF、LVEDD、IVST、LVPWT、右心室游离壁质量、左心室+室间隔质量、RV/（LV+S）均高于干预前，白藜芦醇组LVEF高于糖皮质激素组和对照组，LVEDD、IVST、LVPWT、右心室游离壁质量、左心室+室间隔质量、RV/（LV+S）低于糖皮质激素组和对照组，糖皮质激素组LVEF高于对照组，LVEDD、IVST、LVPWT、右心室游离壁质量、左心室+室间隔质量、RV/（LV+S）低于对照组（P＜0.05）。糖皮质激素组总不良反应发生率高于白藜芦醇组和对照组,差异有统计学意义（P＜0.05）。
结论相对于糖皮质激素，白藜芦醇能有效改善慢性阻塞性肺疾病合并肺源性心脏病SD大鼠的肺功能、延缓心脏功能及结构恶化速度，改善预后，可避免糖皮质激素引起的高血糖、骨质疏松等严重不良反应发生，兼具有效性和安全性；白藜芦醇的上述作用机制尚待进一步研究证实，以期为慢性阻塞性肺疾病合并肺源性心脏病的治疗提供更为有效的依据。

关键词: 肺疾病, 慢性阻塞性；肺心病；白藜芦醇

Abstract: Objective To investigate the effect of resveratrol on pulmonary function and cardiac function in SD rats with chronic obstructive pulmonary disease and pulmonary heart disease.
Methods Forty-five adult male SD rats were randomly divided into resveratrol group, glucocorticoid group and control group with 15 rats in each group. The resveratrol group was given resveratrol intragastric administration for 28 days, the glucocorticoid group was given Budesonide aerosol inhalation for 28 days, and the control group was given normal saline for 28 days. The lung function(CL), peak expiratory flow(PEF), maximum mid expiratory flow curve(MMF) and forced expiratory volume in first 0.3 second/forced vital capacity were compared between the three groups before and after treatment, FEV0.3/FVC, left ventricular ejection fraction(LVEF), left ventricular end diastolic diameter(LVEDd), interventricular septal thickness(IVST) and left ventricular posterior wall thickness(LVPWT), Right ventricular free wall mass, left ventricle and interventricular septum mass, right ventricular free wall mass/left ventricular+ventricular septum mass ratio(RV/（LV+S） were observed.
Results After the intervention, the levels of CL, PEF and MMF in the three groups were lower than those before the intervention, and the levels of FEV0.3/FVC in the resveratrol group were higher than those in the glucocorticoid group and the control group, and the levels of CL, PEF, MMF and FEV0.3/FVC in the glucocorticoid group were higher than those in the control group(P＜0.05). LVEF, LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricular+interventricular septal mass and RV/（LV+S） of the three groups were higher than those before intervention. LVEF of resveratrol group was higher than that of glucocorticoid group and control group. LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricular+ventricular septum mass, RV/（LV+S） were lower than those of glucocorticoid group and control group, and LVEF of glucocorticoid group was higher than that of control group LVEDd, IVST, LVPWT, right ventricular free wall mass, left ventricle+interventricular septum mass, RV/（LV+S） in the control group were lower than those in the control group(P＜0.05). The total incidence of adverse reactions in glucocorticoid group was higher than that in resveratrol group and control group(P＜0.05).
Conclusion Compared with glucocorticoids, resveratrol can effectively improve the lung function of SD rats with chronic obstructive pulmonary disease complicated with pulmonary heart disease, delay the deterioration of cardiac function and structure, improve the prognosis, and avoid the occurrence of severe adverse reactions such as hyperglycemia and osteoporosis caused by glucocorticoids, which has both effectiveness and safety. The above mechanism of resveratrol needs to be further studied. The study confirmed that it is expected to provide more effective clinical basis for the treatment of chronic obstructive pulmonary disease complicated with pulmonary heart disease.

Key words: pulmonary disease, chronic obstructive, pulmonary heart disease, resveratrol

闫姗姗, 赵芳, 肖剑, 张春良. 白藜芦醇在慢性阻塞性肺疾病合并肺源性心脏病SD大鼠肺功能及心脏功能改善中的作用[J]. 河北医科大学学报, doi: 10.3969/j.issn.1007-3205.2020.08.004.

YAN Shan-shan, ZHAO Fang, XIAO Jian, ZHANG Chun-liang. Effect of resveratrol on pulmonary function and cardiac function in SD rats with chronic obstructive pulmonary disease and pulmonary heart disease[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.1007-3205.2020.08.004.

[1]	张欣. 血液CC16、PCT、FKN水平与慢性阻塞性肺疾病患者衰弱的临床研究 [J]. 河北医科大学学报, 2023, 44(9): 1027-1031.
[2]	任杰, 祖力皮喀尔·阿卜杜热合曼, 弓慧, 钟雪梅, 郑爱芳, 李黎. COPD中MicRNA-320c-5p调节SERPINA1基因表达的研究 [J]. 河北医科大学学报, 2023, 44(2): 137-141.
[3]	范素芳, 吕侯强. 血糖、炎症指标与COPD气流受限、治疗预后关联性及临床意义 [J]. 河北医科大学学报, 2023, 44(12): 1436-1441.
[4]	郭立娟, 商焕霞, 张罗元, 席素雅, 贺向红. AECOPD患者外周血NF-κB、IL-34、CCL18水平与预后的关系探讨 [J]. 河北医科大学学报, 2023, 44(10): 1141-1145.
[5]	蒋丽萍, 李文珍, 韦江妹. STC1、TWEAK、miR-183在COPD患者中的表达及相关性研究[J]. 河北医科大学学报, 2022, 43(6): 651-656,670.
[6]	刘梅霞, 姜宏英, 张娜. 吸烟与贫血交互作用影响慢性阻塞性肺疾病易感性的临床研究[J]. 河北医科大学学报, 2022, 43(4): 386-390.
[7]	连雪梅, 李亚男, 章隽, 孙萌, 高永红. 基于HRR法的康复运动处方改善慢性阻塞性肺气肿患者运动能力与躯体症状的效果 [J]. 河北医科大学学报, 2022, 43(10): 1137-1141.
[8]	赵铁梅, 段智梅, 刘扬, 刘凯迪, 华琳, 圣朝军. 血清生物标志物对纤维化性间质性肺疾病预后的预测价值[J]. 河北医科大学学报, 2022, 43(1): 26-30.
[9]	王慧, 杨淼, 任慧敏, 赵婷婷, 薛乾隆, 李文卉. 慢性阻塞性肺疾病急性加重患者营养风险的评估及其对预后的预测价值[J]. 河北医科大学学报, 2021, 42(8): 876-880.
[10]	赵铁梅. 进行性纤维化性间质性肺疾病共识建议解读[J]. 河北医科大学学报, 2021, 42(6): 621-623.
[11]	张梓楠, 厉坤鹏, 陈浩, 肖琳, 冯莹. 有氧运动对慢性阻塞性肺疾病稳定期免疫及循环的影响[J]. 河北医科大学学报, 2021, 42(6): 661-664.
[12]	王正, 王震, 柴书坤, 刘荣惠, 史金英, 孟爱宏. 慢性阻塞性肺疾病合并/未合并支气管扩张患者炎症指标分析[J]. 河北医科大学学报, 2020, 41(8): 888-891.
[13]	柴书坤, 王震, 王小琳, 史金英, 李艳肖, 王正. 经鼻高流量吸氧对AECOPD合并Ⅱ型呼吸衰竭患者疗效及近期预后的影响[J]. 河北医科大学学报, 2020, 41(7): 764-767,828.
[14]	袁胜芳1，宋宁2*，王布1，马士民2，赵建清1. 红细胞分布宽度联合血清胱抑素C早期诊断慢性阻塞性肺疾病继发肺动脉高压的价值[J]. 河北医科大学学报, 2020, 41(6): 624-627,631.
[15]	姚汉玲1，陈德明2，李青林2*，周宁华1. 穿琥宁注射液治疗慢性阻塞性肺病急性加重期效果及对IL-8、hs-CRP、TNF-α水平的影响[J]. 河北医科大学学报, 2020, 41(3): 268-271.

白藜芦醇在慢性阻塞性肺疾病合并肺源性心脏病SD大鼠肺功能及心脏功能改善中的作用

Effect of resveratrol on pulmonary function and cardiac function in SD rats with chronic obstructive pulmonary disease and pulmonary heart disease

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价